TTrialPathMatch Me to Trials
← Back to trials
RecruitingNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Recurrent

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.

Sponsor: Washington University School of Medicine

You may qualify if…

  • ✓ Histologically or cytologically confirmed, previously untreated or recurrent metastatic NSCLC.
  • ✓ Availability of archival biopsy tissue or willingness to undergo a biopsy prior to C1D1 for biomarker analysis, including PD-L1 by IHC using a CLIA-certified test. Results of the PD-L1 testing are not required for enrollment.
  • ✓ Measurable disease per RECIST 1.1.
  • ✓ At least 18 years of age.
  • ✓ ECOG performance status ≤ 1
  • ✓ Adequate organ and marrow function, as defined below:
  • ✓ Absolute neutrophil count ≥ 1.5 K/cumm
  • ✓ Platelets ≥ 100 K/cumm

You may not qualify if…

  • ✕ Mixed histology including small cell lung cancer.
  • ✕ Tumor harboring any of the following:
  • ✕ classic EGFR mutations
  • ✕ HER2 mutation
  • ✕ ALK fusion
  • ✕ ROS1 fusion
  • ✕ RET fusion
  • ✕ NTRK fusion

Where it's recruiting

Missouri

St Louis

Source: ClinicalTrials.gov · NCT07355205 · last updated 2026-07-10

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept · TrialPath